Skip to main content
Premium Trial:

Request an Annual Quote

Adaptive Biotechnologies, Amgen to Develop Sequencing-Based ALL Assay

NEW YORK (GenomeWeb) – Adaptive Biotechnologies plans to collaborate with Amgen to develop and commercialize Adaptive's next-generation sequencing-based immune profiling assay, ClonoSeq, to assess minimal residual disease in patients with acute lymphoblastic leukemia, Adaptive said today.

As part of the collaboration, the companies plan to collect MRD data in order to establish validated thresholds of residual disease that can predict patient outcomes in ALL.

"We are excited to demonstrate through this collaboration that Adaptive's highly accurate and sensitive ClonoSeq assay can be used to give patients and clinicians a more reliable and validated resource to improve monitoring and management of ALL," Adaptive CEO Chad Robins said in a statement.

Adaptive launched ClonoSeq in 2013 as a laboratory-developed test for blood cancers. The company also plans to seek clearance from the US Food and Drug Administration for the assay.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.